Read by QxMD icon Read


Oktay Üçer, Ali Can Albaz, Elif Atag, Aziz Karaoglu, Talha Muezzinoglu
PURPOSE: To investigate the proportion of neoadjuvant chemotherapy (NAC) use in patients with muscle invasive bladder cancer before radical cystectomy and the approach of urologists to this subject. MATERIALS AND METHODS: We invited 242 urologists during the 12th International Urooncology Congress in Turkey to answer a self-administered questionnaire. The questionnaire included questions related to radical cystectomy, lymph node dissection and neoadjuvant chemotherapy that had been performed in patients with muscle invasive bladder cancer by the urologist...
October 10, 2016: Urology Journal
D-H Zermann, W Hoffmann, W Vahlensieck
The primary objectives of modern urooncological treatment concepts are quality of life, reintegration and participation. Urological rehabilitation supports the overcoming of side effects of disease and treatment, which is necessary for the timely return to work life. Social medical assessment reflects the individual overall results of the entire treatment process concerning oncological prognosis, physical and mental capacity and resilience.
January 2017: Der Urologe. Ausg. A
Ramazan Kocaaslan, Yunus Kayalı, Adem Tok, Abdulkadir Tepeler
OBJECTIVE: To analyze the publication rates of full-text journal articles converted from the abstracts presented in the 22(nd) Turkish National Urology Congress in 2012. MATERIAL AND METHODS: A total of 576 abstracts accepted for presentation at the 22(nd) Turkish National Urology Association Meeting were identified from the published abstract book. The abstracts were categorized into subsections such as endourology and pediatric urology. The subsequent publication rate for the studies was evaluated by scanning PubMed Medline...
March 2016: Turkish Journal of Urology
L Skrobek, M Boegemann, A Hegele
What new developments in urooncology were discussed at the 2015 annual meetings of ASCO, EAU, DGU and ESMO? This review summarises news relevant to the daily diagnosis and treatment of prostate, bladder and kidney cancer. While study results seem to change paradigms in the treatment of prostate cancer, particularly in metastatic but still hormone-sensitive stages, immunotherapeutic strategies for the treatment of kidney and urothelial cancer are very promising and might expand the systemic therapeutic options in the years to come...
February 2016: Aktuelle Urologie
T Maurer, H Kübler, J E Gschwend, M Eiber
No abstract text is available yet for this article.
September 2015: Der Urologe. Ausg. A
T Maurer, H Kübler, J E Gschwend, M Eiber
The use of positron emission tomography (PET) is an established method for the diagnosis of urological malignancies. Several tracers are currently available to obtain metabolic information or directly detect molecular targets. While (18)F-FDG-PET is recognized in current guidelines for the staging of seminoma, PET is not used in clinical routine in renal malignancies due to the lack of specific tracers. Despite initial promising results in bladder cancer, no relevant additional diagnostic value with PET using (18)F-FDG or choline-based tracers could be obtained in most patients and therefore should be used with caution or only within clinical trials...
July 2015: Der Urologe. Ausg. A
Kirsten Bouchelouche, Peter L Choyke
Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers...
July 2015: PET Clinics
A Hegele, L Skrobek, M Boegemann
What is new in urooncology in the year 2014? This review gives a brief but comprehensive overview of new developments in diagnosis and treatment of localized as well as advanced prostate, bladder and kidney cancer which have been presented on the occasion of the annual meetings of the European and American urologic and oncological associations in 2014. Attention is particularly directed to those data and results from trials which might be of direct or indirect clinical relevance.
March 2015: Aktuelle Urologie
Nalan Neşe, Banu S Kumbaraci, Dilek E Baydar, Işin Kiliçaslan, Ayşegül A Sari, Sait Şen, Ipek I Gönül, Duygu Kankaya, Yasemin Özlük, Murat Ermete, Ayşim Özağari, Nebil Bal, Saba Kiremitçi, Kürşat Yildiz, Burçin Tuna, Nilay Şen, Kutsal Yörükoğlu
Small cell carcinoma (SmCC) is a rare and aggressive neuroendocrine carcinoma of the bladder. Neuroendocrine carcinomas expressing somatostatin receptors (SSTR) in other viscera such as lung, pancreas, and gastrointestinal system respond to therapy with somatostatin analogs. In the present study, expressions of SSTRs 1 to 5 including type 2A are investigated by immunohistochemistry (IHC) and their relationship with clinicopathologic factors was evaluated. Hundred primary bladder SmCC cases were collected from 12 centers in Turkey...
April 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
Osman İnci, Ebru Taştekin, Hakan Gençhellaç, Özcan Arabacı, Serap İşler, İrfan Hüseyin Atakan
BACKGROUND: Urachal masses observed in adults should be considered malignant unless they are confuted. It is very difficult to differentiate between malignant or benign lesions, including especially calcified foci and solid areas. CASE REPORT: Our case was a 63-year-old male patient who was diagnosed as Behçet's Disease 26 years ago. Upon clinical examination, he was also diagnosed with adenocarcinoma of prostate. He was examined by computerized tomography to define the stage of prostatic adenocarcinoma...
January 2015: Balkan Medical Journal
Stênio Cássio Zequi
No abstract text is available yet for this article.
September 2014: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Piotr Zygmunt Wojcieszak, Sławomir Poletajew, Daniel Rutkowski, Piotr Radziszewski
INTRODUCTION: The Polish National Cancer Registry (KRN) is the most commonly used sources of data on the incidence of cancers including renal cancer in Poland. Until today, the accuracy and completeness of these data has never been verified. MATERIAL AND METHODS: The aim of this study was to assess the completeness and reliability of data on the incidence of renal cancer published by the KRN. KRN data on newly diagnosed cases of renal cancer in Poland (for the whole country) and separately in subjectively selected provinces between 2009 and 2011 were retrospectively compared to the data received from the National Health Fund (NFZ) on the number of radical and partial nephrectomies performed due to renal cancer in the same time frame and regions...
2014: Central European Journal of Urology
Levent Turkeri, Naşide Mangir, Bulent Gunlusoy, Asif Yildirim, Sumer Baltaci, Mustafa Kaplan, Murat Bozlu, Aydin Mungan
In patients with microscopic hematuria there is a need for better identification of those who are at greater risk of harbouring bladder tumors. The RisikoCheck® questionnaire has a strong correlation with the presence of urothelial carcinoma (UC) of the bladder and in combination with other available tests may help identify patients who require detailed clinical investigations due to increased risk of presence of bladder tumors. This study aimed to evaluate the efficacy of RisikoCheck® questionnaire together with NMP-22® (BladderChek®) as a point-of-care urine test in predicting the presence of bladder tumors in patients presenting with microscopic hematuria as the sole finding...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
Björn Georgi, Nina Korzeniewski, Boris Hadaschik, Carsten Grüllich, Wilfried Roth, Holger Sültmann, Sascha Pahernik, Markus Hohenfellner, Stefan Duensing
Treatment of castration resistant prostate cancer (CRPC) continues to represent a major urooncological challenge due to tumor heterogeneity and the inevitable development of therapy resistance. Although androgen deprivation therapy retains an important role in the management of CRPC, recent evidence suggests that a broader spectrum of therapeutic targets may improve patient response and delay development of advanced disease. Genome-wide analyses have identified four major signaling nodes that are most frequently altered in prostate cancer: i) the androgen receptor (AR); ii) the PI3K pathway; iii) the Ras/Raf/MEK/ERK pathway; and iv) the retinoblastoma protein (pRB) signaling pathway...
October 2014: International Journal of Oncology
A Hegele, L Skrobek, A J Schrader
What is new in urooncology in the year 2013? This review gives a brief but comprehensive overview of new developments in diagnosis and treatment of localized as well as advanced prostate, bladder and kidney cancer which have been presented on the occasion of the annual meetings of the European and American urologic and oncological associations in 2013. Attention is particularly directed to those data and results from trials which might be of direct or indirect clinical relevance.
January 2014: Aktuelle Urologie
Katalin Borbély, Lajos Géczi, Miklós Kásler
The wide use of molecular positron emission tomography/computed tomography (PET/CT) imaging in the tumor diagnostics has been playing an important role recently. The clinical role of hybrid imaging (PET/CT, single photon ECT/CT (SPECT/CT)) is growing continuously due to the simultaneous imaging of anatomy and function. Regarding oncology the role of (18)F-fluorodeoxyglucose ((18)F-FDG) PET is proved in several clinical questions, including urooncology. Urologic cancers are associated with low or slightly significant uptake of FDG, due to their more benign behaviour...
December 2013: Magyar Onkologia
E Dahl, F Haller
Targeted therapies and biomarker validation are key drivers in the advancement of personalized oncology which is a growing topic in all clinical areas. Compared with other professions, such as pulmonology and gynecology, development in urology has so far been retarded but has recently gained increasing momentum. A basis for this is the currently growing and in future accelerated application of new knowledge derived from molecular biology in the field of uropathology. The rapid gain of knowledge is driven by a whole new class of analytical methods, such as massively parallel sequencing (deep sequencing or next generation sequencing), which enables analysis of virtually a new universe of potential biomarkers...
July 2013: Der Urologe. Ausg. A
C G Stöhr, R Stöhr, A Rogler, K Amann, R Knüchel-Clarke, A Hartmann
The approval of new therapeutic procedures for the three main malignancies of the urogenital tract in recent years has generated a need for personalization of urooncology. As a consequence the diagnostic procedures are no longer limited to histology and immunohistochemistry but also include the analysis of genetic alterations (mutations and chromosomal aberrations).
July 2013: Der Urologe. Ausg. A
M Hanus, M Matoušková, L Dušek
There is a remarkably rising incidence of histologically proven prostate cancer since the introduction of prostatic specific antigen (PSA) test into clinical practice. TNM classification of these tumors in about 50% of cases is in categories T1,2 N0M0, Gleason score 7 and PSA level under 10 ug/ l (Graph 1). Such tumors are considered low risk and therefore conservative approach seems to be acceptable therapeutic variant. In spite of nonsurgical approach, patients with the so called early stage diagnosed disease have been almost only indicated for radical prostatectomy with a therapeutic approach...
2013: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
Narmada P Gupta
Robotic surgery is a significant advance in the realm of urologic surgery esp. for uro genital cancers and reconstructive procedures. Robotic surgery is associated with precision and ease in dissection, incision and suturing with less steep learning curve in comparison to laparoscopy. It provides all benefits of minimally invasive surgery. At present, cost is a prohibitive factor. Robotic surgery is going to stay and is going to open new avenues for, image guided and telepresence surgery.
June 2012: Indian Journal of Surgical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"